Pharmaceutics (Jun 2022)

<i>Crocus sativus</i> L. Petal Extract Inhibits Inflammation and Osteoclastogenesis in RAW 264.7 Cell Model

  • Ciriana Orabona,
  • Elena Orecchini,
  • Claudia Volpi,
  • Federico Bacaloni,
  • Eleonora Panfili,
  • Cinzia Pagano,
  • Luana Perioli,
  • Maria Laura Belladonna

DOI
https://doi.org/10.3390/pharmaceutics14061290
Journal volume & issue
Vol. 14, no. 6
p. 1290

Abstract

Read online

The dried stigmas of Crocus sativus L. (Iridaceae) are traditionally processed to produce saffron, a spice widely used as a food coloring and flavoring agent, which is important in the pharmaceutical and textile dye-producing industries. The labor-intensive by-hand harvesting and the use of only a small amount of each flower cause saffron to be the most expensive spice in the world. Crocus sp. petals are by-products of saffron production and represent an interesting raw material for the preparation of extracts intended for health protection in the perspective of a circular economy. In the present study, ethanolic extract from Crocus sativus L. petals (Crocus sativus L. petal extract, CsPE) was tested on macrophages by in vitro models of inflammation and osteoclastogenesis. The extract was found to be endowed with anti-inflammatory activity, significantly reducing the nitric oxide production and IL-6 release by RAW 264.7 murine cells. Moreover, CsPE demonstrated an anti-osteoclastogenic effect, as revealed by a complete inhibition of tartrate-resistant acid phosphatase (TRAP)-positive osteoclast formation and a decreased expression of key osteoclast-related genes. This study, which focuses on the macrophage as the target cell of the bioactive extract from Crocus sativus L. petals, suggests that the petal by-product of saffron processing can usefully be part of a circular economy network aimed at producing an extract that potentially prevents bone disruption.

Keywords